mani
virus
investig
develop
genet
vaccin
ideal
one
must
endow
mani
properti
qualiti
quantiti
immunolog
respons
induc
encod
antigen
safeti
product
larg
scale
basi
viral
base
vaccin
must
also
deal
potenti
problem
preexist
antivector
immun
sever
viral
vaccin
vector
emerg
date
rel
advantag
limit
depend
propos
applic
recent
success
fl
ect
divers
improv
develop
new
adenoviru
serotyp
primeboost
regim
chapter
describ
featur
four
viral
vector
system
base
poxvirus
adenovirus
alphavirus
lentivirus
recent
result
follow
use
particular
emphasi
clinic
research
highlight
challeng
success
vaccin
undeni
success
induc
immun
respons
notabl
neutral
antibodi
prevent
viral
bacteri
infect
howev
protect
complex
pathogen
human
immunod
fi
cienci
viru
hiv
hepat
c
viru
hcv
plasmodium
falciparum
mycobacterium
tuberculosi
tb
cancer
necessari
engag
arm
adapt
immun
system
lymphocyt
preclin
clinic
evid
support
role
cell
immun
particular
cell
control
andor
clearanc
diseas
kim
ahm
therefor
rapidli
expand
fi
eld
vaccinolog
develop
socal
genet
vaccin
design
induc
antigenspeci
fi
c
cell
suf
fi
cient
magnitud
necessari
phenotyp
effector
function
directli
contribut
pathogen
clearanc
rather
cell
help
b
cell
lead
protect
antibodi
respons
one
way
induc
cell
respons
given
antigen
express
antigen
intracellularli
along
suitabl
pathogenderiv
innat
activ
gene
deliveri
genet
genebas
vaccin
attempt
use
physiolog
antigen
process
major
histocompat
complex
mhc
class
present
activ
cell
respons
genet
vaccin
capabl
stimul
antibodi
cell
hold
real
promis
achiev
ef
fi
caci
tabl
list
pro
con
genet
vaccin
dna
vaccin
initi
thought
ideal
way
induc
cell
respons
liu
reyessandov
ertl
intramuscular
intraderm
inject
express
encod
antigen
insid
host
cell
result
cellular
humor
immun
vaccin
simpl
produc
manipul
coexpress
cytokin
molecul
intend
enhanc
immun
respons
simpl
produc
unfortun
earli
success
preclin
studi
translat
clinic
trial
wherea
dna
vaccin
safe
use
induc
cell
respons
human
low
magnitud
effort
increas
immunogen
use
new
devic
genegun
result
ef
fi
cient
deliveri
dose
could
consider
reduc
respons
increas
despit
sever
effort
fi
nd
adjuv
increas
immunogen
dna
vaccin
human
success
far
modest
hold
true
peptidebas
vaccin
nardin
perez
et
al
research
concentr
develop
adjuv
increas
cell
immunogen
protein
vaccin
foge
et
al
although
respons
induc
preclin
studi
high
magnitud
mani
case
yet
test
clinic
studi
numer
viral
vector
studi
use
genebas
vaccin
strategi
virusderiv
vector
offer
sever
advantag
tradit
vaccin
technolog
fi
rst
ef
fi
cient
deliveri
exogen
gene
target
cell
advantag
includ
high
level
product
protein
antigen
within
cell
immun
host
potenti
adjuv
effect
viral
vector
system
possibl
ef
fi
cient
deliveri
antigen
directli
compon
immun
system
commonli
use
vector
deriv
adenovirus
poxvirus
alphavirus
lentivirus
wide
consensu
ideal
vector
develop
genet
vaccin
must
endow
mani
properti
eg
qualiti
quantiti
immunolog
respons
induc
encod
antigen
safeti
product
condit
compat
industri
scale
compar
assess
strength
weak
variou
genet
vector
report
tabl
featur
four
viral
vector
system
mention
recent
result
follow
use
review
particular
emphasi
clinic
research
highlight
challeng
success
look
toward
futur
deploy
among
viral
vector
investig
vaccin
purpos
adenoviru
ad
vector
receiv
consider
attent
today
stand
among
potent
tool
avail
induct
antibodi
cell
respons
mice
primat
human
barefoot
et
al
barouch
bett
et
al
harro
et
al
ledgerwood
et
al
liu
et
al
tatsi
ertl
human
adenovirus
attract
viral
vector
number
reason
possess
stabl
virion
insert
foreign
gene
delet
also
adenovirus
wide
cell
tropism
transfer
inform
remain
epichromosom
thu
avoid
risk
insert
mutagenesi
replicationdefect
adenovirus
engin
delet
gene
locu
requir
viral
replic
virus
propag
easili
good
yield
complement
cell
line
express
adenoviru
serotyp
tatsi
et
al
preclin
clinic
result
show
superior
adenovirusvector
vaccin
base
common
human
induct
cell
respons
casimiro
et
al
casimiro
et
al
duerr
et
al
preclin
studi
vector
includ
vaccin
ebola
sever
acut
respiratori
syndrom
sar
hiv
anthrax
bangari
mittal
barouch
shiver
et
al
sullivan
et
al
clinic
studi
vector
encod
hiv
tb
ebola
antigen
complet
progress
catanzaro
et
al
ledgerwood
et
al
mcelrath
et
al
priddi
et
al
howev
adenoviru
highli
immunogen
per
se
ad
vectorspeci
fi
c
immun
respons
result
lack
prolong
express
newli
deliv
gene
upon
readministr
vector
lasaro
ertl
importantli
major
problem
human
high
titr
neutral
antibodi
sever
adenoviru
serotyp
includ
owe
exposur
sinc
childhood
neg
affect
perform
vector
lasaro
ertl
recent
studi
shown
preexist
immun
capabl
signi
fi
cantli
blunt
immunolog
respons
induc
vector
vaccin
rodent
nonhuman
primat
phase
clinic
trial
human
casimiro
et
al
catanzaro
et
al
mcelrath
et
al
priddi
et
al
variou
attempt
made
overcom
problem
preexist
immun
thu
exploit
full
potenti
adenoviru
vector
develop
vaccin
one
strategi
identi
fi
cation
develop
rare
human
serotyp
geisbert
et
al
kahl
et
al
lemckert
et
al
radosev
et
al
soloff
et
al
adapt
altern
serotyp
requir
method
process
research
develop
safeti
test
furthermor
data
suggest
rare
serotyp
may
less
immunogen
anoth
strategi
modi
fi
cation
capsid
protein
shell
contain
hexon
penton
subunit
host
antibodi
neutral
direct
hypervari
region
hvr
hexon
subunit
robert
colleagu
robert
et
al
exchang
hvr
rare
adenoviru
serotyp
gener
chimaer
adenoviru
could
potenti
evad
neutral
antibodi
respons
result
viru
retain
abil
grow
cultur
importantli
immunogen
chimaera
compar
chimaera
administ
mice
monkey
antibodi
immun
decreas
immunogen
vector
data
provid
proofofconcept
viral
vaccin
vector
engin
evad
preexist
immun
vaccin
develop
show
hvrchimaer
virus
manufactur
stabl
gene
insert
pass
regulatori
review
fi
nalli
immunogen
human
preexist
immun
adenovirus
isol
chimpanze
chad
also
well
character
develop
vector
farina
et
al
roy
et
al
tatsi
et
al
simian
adenovirus
known
caus
patholog
ill
human
lowno
seropreval
human
popul
lasaro
ertl
equatori
africa
natur
habitat
chimpanze
seropreval
higher
still
signi
fi
cantli
fi
rst
report
use
chad
vector
involv
express
rabi
viru
glycoprotein
show
induct
high
level
protect
antibodi
mice
xiang
et
al
simian
adenovector
util
cell
vaccin
hiv
induc
virusspeci
fi
c
cell
respons
mice
macaqu
fitzgerald
et
al
reyessandov
et
al
preerythrocyt
malaria
vaccin
reyessandov
et
al
recent
colloca
colleagu
report
larg
screen
sever
adenovirus
isol
chimpanze
identi
fi
ed
sever
adenovirus
meet
necessari
requir
vaccin
develop
chimpanze
adenovirus
locu
delet
render
viru
replic
de
fi
cient
allow
transcomplement
complement
cell
line
chimpanze
deriv
adenovirus
exhibit
high
sequenc
similar
genom
organ
human
adenovirus
classi
fi
ed
subgroup
base
sequenc
homolog
hexon
protein
phylogenet
analysi
hexon
simian
human
adenovirus
show
substanti
overlap
indic
clear
sequenc
featur
distinguish
simian
human
adenoviru
inde
sequenc
suggest
one
larg
famili
higher
primat
adenovirus
potenc
chimpanze
deriv
ad
vector
assess
mice
macaqu
recent
human
colloca
et
al
ohara
et
al
sheehi
et
al
cell
immunogen
vector
match
even
exceed
immunogen
standard
vector
use
compar
safeti
vector
similar
human
adenoviru
vector
suggest
might
suitabl
widespread
use
addit
adenoviru
vector
poxvirus
among
heavili
exploit
vaccin
develop
larg
attribut
extens
success
use
smallpox
vaccin
relat
modi
fi
ed
vaccinia
ankara
mva
provid
knowledg
human
safeti
togeth
seri
properti
includ
larg
gene
capac
insert
foreign
gene
broad
tropism
viru
mammalian
cell
product
antigen
short
period
time
local
viru
cytoplasm
thu
avoid
integr
risk
might
occur
retrovir
vector
vaccin
base
poxvirus
deriv
vaccinia
viru
member
avipox
genu
vacciniahiv
recombin
evalu
clinic
trial
howev
larg
due
concern
use
replic
vector
safer
nonrepl
poxviru
vector
focu
extens
develop
attenu
deriv
vaccinia
viru
use
vaccin
platform
includ
nyvac
deriv
copenhagen
strain
vaccinia
render
replic
incompet
speci
fi
c
engin
delet
parrino
graham
avipox
vector
canarypox
alvac
fowlpox
fpv
restrict
growth
avian
cell
infect
mammalian
cell
replic
franchini
et
al
mva
latter
origin
develop
smallpox
vaccin
obtain
follow
extens
serial
passag
primari
chicken
embryo
fi
broblast
process
attenu
mva
underw
delet
kb
genom
compar
parent
strain
includ
number
gene
contribut
viral
evas
host
immun
respons
determin
viru
host
rang
antoin
et
al
meyer
et
al
result
mva
unabl
replic
product
mammalian
cell
type
includ
primari
human
cell
result
inabl
mva
undergo
one
infect
cycl
human
host
imbu
viru
inher
safeti
demonstr
histor
immun
individu
smallpox
erad
campaign
recent
safeti
mva
demonstr
preclin
studi
immuned
fi
cient
mice
immunesuppress
macaqu
stittelaar
et
al
wyatt
et
al
phase
clinic
trial
evalu
mva
nextgener
smallpox
vaccin
parrino
et
al
desir
safeti
pro
fi
le
exhibit
mva
concert
abil
express
high
level
larg
number
foreign
gene
render
mva
lead
candid
evalu
vaccin
vector
array
infecti
diseas
human
cancer
alphavirus
develop
vaccin
vector
includ
venezuelan
equin
enceph
viru
vee
sindbi
viru
sin
semliki
forest
viru
sfv
veesin
chimaera
greer
et
al
thornburg
et
al
alphavirus
singlestrand
positivesens
rna
virus
replic
cytoplasm
infect
cell
therefor
potenti
integr
host
genom
origin
circumv
safeti
concern
alphaviru
vector
engin
nonrepl
replicon
particl
gene
encod
structur
product
delet
accommod
foreign
gene
kb
structur
protein
provid
tran
two
helper
transcript
lack
packag
signal
importantli
vector
natur
target
dendrit
cell
dc
drain
lymph
node
transgen
express
high
level
lead
good
immun
respons
davi
et
al
immunogen
enhanc
selfampli
fi
cation
vector
rna
occur
doublestrand
rna
intermedi
stimul
activ
interferon
cascad
multipl
innat
signal
pathway
naslund
et
al
vector
also
induc
apoptosi
cell
type
releas
apoptot
bodi
ef
fi
cientli
taken
antigen
present
cell
apc
result
enhanc
immun
crossprim
perri
et
al
featur
overal
lack
preexist
immun
alphavirus
human
popul
underscor
potenti
vaccin
vehicl
three
type
vector
develop
viruslik
particl
vlp
layer
dnarna
vector
replicationcompet
vector
vlp
contain
replicon
rna
defect
sinc
contain
clone
gene
place
structur
protein
gene
thu
abl
undergo
one
cycl
express
produc
transfect
vector
rna
helper
rna
encod
structur
protein
layer
dnarna
vector
express
sfv
replicon
cdna
copi
via
cytomegaloviru
promot
replicationcompet
vector
contain
transgen
addit
structur
protein
gene
veebas
propagationdefect
viruslik
replicon
particl
vrp
shown
induc
high
titer
antibodi
robust
antigenspeci
fi
c
cell
respons
encod
antigen
mice
bernstein
et
al
davi
et
al
durso
et
al
greer
et
al
naslund
et
al
perri
et
al
recent
healthi
human
subject
bernstein
et
al
time
neutral
antivector
immun
appear
preclud
bene
fi
repetit
booster
vaccin
mice
gupta
et
al
oppos
viral
vector
veesin
chimaera
develop
safeti
concern
vee
pathogen
human
contrast
sin
nonpathogen
mice
chimer
vector
vee
contribut
replicon
compon
sin
envelop
glycoprotein
packag
compon
shown
elicit
potent
immun
respons
vee
superior
sin
sinve
chimera
contain
sin
replicon
compon
vee
packag
compon
perri
et
al
greater
respons
induc
vee
may
relat
greater
level
vivo
replic
resist
vee
b
interferon
subsequ
studi
macaqu
demonstr
chimer
veesin
vector
elicit
potent
system
mucos
immun
respons
insert
hiv
envelop
gene
product
compar
sin
vector
gupta
et
al
combin
approach
involv
prime
veesin
replicon
encod
hiv
simian
immunod
fi
cienci
viru
siv
gene
follow
boost
hiv
envelop
protein
elicit
cellular
immun
neutral
antibodi
result
signi
fi
cantli
lower
acut
viremia
follow
exposur
simian
human
immunod
fi
cienci
viru
shiv
recent
recombin
lentivir
vector
lv
gain
substanti
interest
altern
method
elicit
antigen
speci
fi
c
tcell
immun
collin
cerundolo
collin
essling
et
al
et
al
hu
et
al
immun
lv
observ
induc
potent
durabl
cell
respons
preclin
model
like
relat
capac
transduc
nondivid
cell
includ
dc
target
tissu
enabl
persist
antigen
present
high
level
express
transgen
low
interf
antivector
immun
respons
shown
lv
encod
polyepitop
induc
broad
respons
mice
iglesia
et
al
singl
intramuscular
administr
hivbas
lv
express
viral
antigen
elicit
strong
cellmedi
immun
respons
buffa
et
al
importantli
beignon
colleagu
recent
provid
fi
rst
evid
lv
express
siv
gag
protein
abl
induc
control
viral
replic
monkey
challeng
high
dose
siv
beignon
et
al
fulli
har
great
potenti
dc
gatekeep
initi
maintain
immun
yang
colleagu
yang
et
al
report
gener
lv
system
bear
mutat
glycoprotein
deriv
sin
capabl
target
dc
bind
speci
fi
c
intercellular
adhes
nonintegrin
dcsign
despit
desir
advantag
lv
effect
deliv
transgen
dc
vector
integr
host
cell
genom
provok
safeti
concern
consequ
insert
mutagenesi
bokhoven
et
al
montini
et
al
order
improv
safeti
pro
fi
le
lv
consider
effort
made
gener
integrationd
fi
cient
lv
idlv
interrupt
function
integras
attach
site
vector
backbon
wanisch
yanezmunoz
although
integr
speci
fi
calli
inhibit
result
idlv
accomplish
transient
gene
transfer
divid
cell
maintain
durabl
transgen
express
nondivid
cell
philipp
et
al
initi
experi
involv
singl
dose
inject
idlv
encod
envelop
protein
either
negri
et
al
west
nile
viru
coutant
et
al
result
signi
fi
cant
prolong
immun
respons
deliv
antigen
base
recent
report
show
potenti
idlv
induc
antigenspeci
fi
c
immun
respons
upon
vivo
immun
viral
tumor
antigen
hu
et
al
karwacz
et
al
negri
et
al
mous
model
develop
term
bulk
product
lope
et
al
valid
idlv
includ
comparison
vaccin
protocol
use
nonhuman
primat
model
warrant
main
limit
vaccin
approach
base
viral
vector
link
induct
antivector
immun
fi
rst
immun
fact
repeat
administr
recombin
adenovirus
mva
vaccin
vector
typic
result
increasingli
diminish
ef
fi
caci
booster
immun
due
elicit
vectorspeci
fi
c
neutral
antibodi
respons
casimiro
et
al
hirsch
et
al
sever
studi
shown
primingboost
differ
vaccin
vector
elicit
higher
immun
respons
transgeneencod
antigen
repeat
vaccin
individu
vector
thu
combin
use
vector
gener
de
fi
ned
heterolog
primeboost
regimen
best
way
overcom
antivir
immun
induc
fi
rst
vaccin
maxim
host
respons
vaccin
insert
initi
heterolog
primeboost
protocol
common
vaccin
insert
often
use
dna
plasmid
prime
immun
system
howev
recent
interest
grown
combin
use
differ
viral
vector
sequenc
administr
fl
uenc
magnitud
natur
induc
immun
respons
multipl
approach
test
anim
model
human
includ
dnamva
dnanyvac
fpvmva
admva
heterolog
adad
dnasendai
viru
target
wide
rang
diseas
malaria
tb
hcv
cancer
tabl
consist
observ
throughout
studi
differenti
abil
certain
vector
prime
boost
respons
dna
vaccin
fpv
good
prime
vector
wherea
poxvirus
mva
nyvac
consist
abl
boost
cell
respons
prime
mean
util
mvabas
vaccin
prime
immun
respons
foreign
antigen
appear
limit
due
unfavor
competit
immunodomin
rel
larg
number
vectorspeci
fi
c
gene
product
antoin
et
al
much
smaller
number
intend
vaccin
antigen
smith
et
al
b
larg
bodi
data
indic
gener
recombin
ad
prime
cell
b
cell
respons
remark
well
therefor
optim
regimen
would
use
adenoviru
fi
rst
prime
mva
later
boost
previous
vaccin
induc
immun
respons
immun
protocol
base
adenoviru
prime
follow
mva
demonstr
power
strategi
induc
potent
durabl
cell
respons
strategi
enabl
induct
protect
immun
respons
mous
malaria
siv
challeng
rhesu
monkey
recent
work
establish
use
primeboost
immun
regimen
induc
b
cell
well
cell
respons
particular
admva
draper
et
al
heterolog
adad
viral
vector
prime
follow
protein
boost
durso
et
al
har
abil
viral
vector
induc
potent
cell
respons
protein
induc
high
antibodi
titer
cell
induct
arm
adapt
immun
respons
like
bene
fi
cial
protect
pathogen
malaria
parasit
mani
virus
better
understand
differ
viral
vector
affect
induct
b
cell
respons
essenti
improv
ration
design
vaccin
primeboost
strategi
tailor
induc
optim
antibodi
respons
even
though
viral
vector
vaccin
stand
among
potent
platform
induct
cell
respons
appar
better
vaccin
still
need
improv
magnitud
breadth
qualiti
induc
cell
respons
experiment
immunogen
may
improv
coadministr
cytokin
andor
pathogen
associ
molecular
pattern
fusion
antigen
molecular
domain
enhanc
antigen
present
substanti
amount
time
use
ci
act
sequenc
enhanc
ef
fi
caci
vaccin
dna
vaccin
territori
mani
strategi
increas
respons
adenoviru
vaccin
vector
publish
far
holst
et
al
tempt
specul
viral
vector
vaccin
contain
suf
fi
cient
pathogenassoci
molecular
pattern
substitut
mani
cytokin
coadminist
vaccin
compar
dna
vaccin
viral
vector
ef
fi
cientli
enter
transduc
cell
includ
profession
antigen
present
cell
gener
induc
high
level
protein
caltech
ucla
express
transduc
cell
induc
substanti
innat
immun
activ
regard
close
natur
infect
vaccin
live
attenu
vaccin
improv
safeti
pro
fi
le
downsid
vector
antigen
compet
encod
vaccin
antigen
focus
respons
immunodomin
epitop
schirmbeck
et
al
search
adenoviru
vaccin
modi
fi
cation
might
lead
broader
cell
respons
holst
cowork
decid
improv
mhc
class
ii
antigen
present
coval
link
encod
antigen
mhc
class
ii
associ
invari
chain
holst
et
al
surprisingli
strategi
improv
cell
respons
also
kinet
breadth
magnitud
durabl
cell
respons
via
increas
mhc
class
present
holst
et
al
differ
strategi
gener
potent
cell
respons
use
adenoviru
vector
recent
describ
appledorn
et
al
strategi
use
vector
express
potent
tolllik
receptor
tlr
agonist
deriv
eimeria
tenella
ea
adjuv
improv
immun
respons
hiv
gag
vaccin
express
rea
elicit
signi
fi
cantli
increas
tlr
mediat
innat
immun
respons
measur
fl
ux
plasma
cytokin
chemokin
activ
innat
immun
respond
cell
mice
therefor
simultan
express
rea
potenti
similar
tlr
ligand
ad
vector
serv
enhanc
cell
mediat
immun
respons
pathogen
deriv
antigen
express
vector
approach
improv
viral
vectorinduc
immun
base
antigen
link
herp
viru
protein
calreticulin
test
sin
replicon
particl
cheng
et
al
vaccinia
vector
hsieh
et
al
respect
herp
viral
glycoprotein
test
use
ad
vector
lasaro
et
al
highli
activ
ci
act
agent
identi
fi
ed
viral
vector
theoret
possibl
boost
antigen
speci
fi
c
immun
respons
induc
neglig
vector
immun
futur
studi
need
determin
theoret
opportun
exploit
allow
ef
fi
cient
repeat
administr
viru
vector
vaccin
vaccin
base
viral
vector
vaccin
act
directli
cell
mediat
immun
current
market
use
human
howev
vaccin
japanes
enceph
viru
jev
use
attenu
jellow
fever
viru
encod
jev
premenv
protein
develop
sano
fi
pasteur
complet
phase
iii
trial
market
author
applic
endem
area
fi
led
appaiahgari
et
al
jev
vaccin
known
therefor
pois
fi
rst
human
viral
vector
vaccin
market
also
viral
vector
vaccin
current
use
veterinari
diseas
approv
vaccin
includ
ad
fpv
attenu
yfv
vaccinia
viru
vector
relev
potenti
human
viral
vector
vaccin
wit
number
clinic
trial
complet
underway
draper
heeney
tabl
report
summari
viralvector
vaccin
primeboost
combin
advanc
clinic
trial
highlight
preponder
poxviru
ad
vector
initi
clinic
experi
adenoviru
vaccin
base
use
deriv
vector
candid
vaccin
pathogen
includ
malaria
parasit
fl
uenza
viru
despit
potent
immunogen
approach
suffer
setback
vaccin
step
trial
fail
reduc
might
even
increas
rate
hiv
infect
men
uncircumcis
preexist
antibodi
speci
fi
c
mcelrath
et
al
howev
recent
analys
trial
con
fi
rm
causal
correl
serostatu
increas
acquisit
hiv
obrien
et
al
continu
interest
pursu
ad
vector
either
combin
approach
vaccin
vector
use
human
serotyp
low
seropreval
deriv
chimpanze
recent
barn
colleagu
show
possibl
gener
cell
respons
hcv
magnitud
qualiti
associ
protect
immun
healthi
adult
use
simian
adenovir
vector
vaccin
differ
simian
adenoviru
vaccin
encod
malaria
antigen
also
induc
potent
long
last
cell
respons
ohara
et
al
sheehi
et
al
human
mvabas
vaccin
hivacquir
immun
de
fi
cienci
syndrom
vasan
et
al
malaria
moorthi
et
al
b
tb
hawkridg
et
al
human
papilloma
viru
induc
cervic
intraepitheli
neoplasia
corona
et
al
melanoma
smith
et
al
b
evalu
human
clinic
trial
phase
studi
alphavirusbas
vaccin
cytomegaloviru
complet
bernstein
et
al
primeboost
strategi
heterolog
vector
show
promis
clinic
trial
indic
moder
success
rv
trial
rerksngarm
et
al
studi
conduct
thailand
studi
particip
show
statist
signi
fi
cant
trend
toward
prevent
hiv
infect
atrisk
popul
vaccin
regimen
employ
heterolog
primeboost
strategi
compris
canarypox
vector
alvachiv
sano
fi
pasteur
follow
protein
subunit
alum
adjuv
aidsvax
global
solut
infecti
diseas
booster
vaccin
aidsvax
vaccin
achiev
protect
immun
despit
previou
lack
ef
fi
caci
aidsvax
alon
phase
iii
trial
highlight
key
properti
viral
vector
vaccin
platform
combin
plethora
permut
achiev
desir
immunolog
endpoint
anoth
exampl
primeboost
protocol
clinic
pave
studi
redesign
hvtn
dnaadenoviru
primeboost
vaccin
includ
three
envelop
clade
b
c
well
gag
pol
nef
iavi
report
result
phase
iia
random
clinic
trial
multiclad
dna
prime
follow
multiclad
vaccin
boost
healthi
adult
recent
publish
churchyard
et
al
show
vaccin
regimen
welltoler
induc
polyfunct
cell
still
primeboost
strategi
use
dna
mva
vector
express
mani
differ
hiv
antigen
rerksngarm
et
al
base
preclin
studi
show
adenoviru
prime
follow
mva
boost
power
strategi
induc
potent
durabl
tcell
respons
protocol
enter
clinic
test
excel
result
sever
recent
studi
shown
induct
broad
potent
sustain
cell
respons
human
volunt
prime
simian
adenovir
vector
boost
mva
encod
antigen
deriv
plasmodium
falciparum
ohara
et
al
sheehi
et
al
viral
vector
manufactur
larg
scale
thermost
formul
avail
alcock
et
al
suf
fi
cient
clinic
research
conduct
establish
replic
de
fi
cient
viral
vector
vaccin
lead
genet
vaccin
fi
eld
induc
strong
broad
respons
moreov
ef
fi
caci
studi
cell
induc
vaccin
number
diseas
preclin
model
fi
nalli
demonstr
valid
approach
fi
lling
gap
defens
infecti
diseas
form
cancer
array
choic
vector
vaccin
develop
appar
success
speci
fi
c
vaccin
applic
fl
ect
larg
part
vector
select
fi
rst
consider
choos
vector
whether
use
prophylact
therapeut
applic
peopl
alreadi
infect
infecti
agent
hiv
bene
fi
therapeut
vaccin
attempt
awak
strengthen
immun
respons
fi
nalli
clear
infect
may
outweigh
risk
attribut
vector
contrast
prophylact
vaccin
intend
healthi
peopl
adult
also
children
infant
therefor
safeti
paramount
import
regard
hiv
vaccin
real
possibl
potenti
vaccine
target
popul
alreadi
hivposit
perhap
immun
suppress
make
safeti
viral
vector
great
import
vector
select
also
requir
thorough
understand
biolog
infecti
agent
vaccin
develop
knowledg
cours
result
diseas
natur
recoveri
diseas
often
highlight
immun
respons
correl
control
erad
infecti
agent
provid
critic
inform
regard
type
immun
respons
desir
cellular
andor
humor
system
mucos
inde
variou
vaccin
vector
abil
differenti
induc
immun
respons
compon
shown
tabl
mode
transmiss
infecti
agent
also
impact
vector
choic
vaccin
rout
ie
system
mucos
practic
consider
import
scienti
fi
c
one
fi
nal
goal
vaccin
proven
effect
clinic
trial
develop
manufactur
strategi
abl
provid
vaccin
dose
use
million
peopl
worldwid
system
larg
scale
product
must
avail
viral
recombin
must
genet
stabl
order
maintain
integr
multipl
passag
order
reach
desir
quantiti
vaccin
materi
addit
global
indic
vaccin
impli
use
develop
world
intact
cold
chain
ship
distribut
storag
sophist
equip
vaccin
administr
alway
avail
therefor
vaccin
physic
stabl
requir
freez
even
refriger
prefer
needleless
vaccin
administ
intranas
oral
rout
altern
administr
rout
enhanc
conveni
safeti
elicit
local
system
immun
respons
thu
potenti
provid
protect
pathogen
site
entri
recombin
encod
antigen
success
lyophil
embed
entericco
capsul
resist
acid
stomach
environ
deliv
vaccin
directli
intestin
tract
oral
immun
macaqu
capsul
prime
antigenspeci
fi
c
mucos
system
immun
respons
mercier
et
al
nasal
rout
offer
one
promis
opportun
vaccin
administr
innov
strategi
use
research
industri
includ
new
mucos
adjuv
mucoadhes
polym
prolong
exposur
mucos
vaccin
intranas
deliveri
system
spray
devic
flumist
astrazeneca
canada
inc
fi
rst
intranas
fl
uenza
vaccin
market
adenovirusbas
vaccin
might
among
best
candid
nasal
deliveri
given
natur
tropism
nasal
mucou
membran
abil
activ
innat
immun
respons
tutykhina
et
al
even
skin
known
highli
immunogen
vaccin
site
due
eas
access
immun
system
microvasculatur
consid
unpract
convent
intraderm
inject
complex
unreli
procedur
requir
skill
personnel
gain
new
interest
thank
recent
develop
minim
invas
technolog
includ
vaccineco
solid
dissolv
microneedl
patch
current
preclin
evalu
protein
dna
viral
vector
vaccin
carey
et
al
fi
eld
viral
vector
vaccin
highli
dynam
develop
product
base
viral
vector
accompani
next
year
advanc
technolog
vector
manufactur
stabil
vaccin
administr
enhanc
vaccineinduc
immun
overcom
immunodomin
vector
antigen
transgen
antigen
despit
complex
pose
protocol
optim
heterolog
primeboost
vaccin
regimen
strategi
hold
enorm
promis
prevent
rang
infecti
diseas
immunotherapi
cancer
